Healthcare Breakthrough: Enlitic and Laitek Join Forces

Patients and healthcare providers alike are tired of dealing with outdated, fragmented systems that make accessing and sharing data feel like pulling teeth.

You know that moment when you discover a life hack so good, you’re left wondering, “Why didn’t anyone think of this sooner?”

That’s exactly how we feel about Enlitic acquiring Laitek. 

For years, healthcare data management has been the stubborn puzzle piece that just wouldn’t fit—until now.

This article will show you why this partnership is exactly what the doctor ordered (pun absolutely intended) and how it’s set to make healthcare smarter, faster, and a lot less frustrating for everyone involved.

In the words of Enlitic's CEO, Michael Sistenich, “The acquisition of Laitek, coupled with the growth trajectory of Enlitic, will enhance our capabilities to deliver superior healthcare solutions to our clients. By helping to address critical bottlenecks that impede the efficient flow of data through healthcare systems, we are not only improving operational efficiency for our clients and partners, but also improving patients’ care outcomes.”

Now, let’s break down the buzzworthy details about this game-changing acquisition:

The Scoop on the Laitek Acquisition

• Laitek’s Legacy: Founded in the totally rad 1980s, Laitek is a big-league player in medical imaging data migration and routing. They specialize in helping healthcare systems move and manage imaging data seamlessly. Think MRI, CT scans, and ultrasounds—but faster, smarter, and better.
• Revenue Stats: Laitek brought in a cool $6.8M in FY23, thanks to their recurring contracts and software licensing deals. With a team of 55 split between the US and Romania, they’re making waves in the healthcare tech space.
• Cost & Revenue Synergies: Enlitic expects to save about $1M annually within the first year of ownership. By year three, the acquisition could rake in an extra $5M in revenue synergies. That’s some serious ROI.
• Strategic Fit: Bringing Laitek under Enlitic’s wing is like assembling the dream team. This move:
  • Boosts the value of Enlitic’s use cases.
  • Brings critical tech in-house for more control.
  • Helps pinpoint high-value sales leads.
  • Adds shareholder value.

Combined, the two companies are looking at a juicy pipeline worth up to $108.4M—with efficiency and revenue synergies sweetening the deal.

Meet the Man Steering the Ship

CEO Michael Sistenich is no stranger to making bold moves.

With over 24 years of experience in investment banking, corporate finance, and asset management, he’s like the Tony Stark of healthcare investments.

Notable highlights:

• Co-founded Aurenda Partners.
• Launched the first European healthcare hedge fund managing €500M.
• Previously led the €6.5B DWS Investments healthcare franchise.

When it comes to scaling businesses and creating value, Michael’s got the Midas touch.

Why This Matters for Enlitic

• Who They Are: Enlitic, an ASX-listed AI software company, is revolutionizing how radiology data (like X-rays, CTs, and MRIs) is handled. Their tech enhances clinical workflows, boosts efficiency, and builds the foundation for real-world evidence platforms.
• Board & Leadership: The Enlitic team has deep roots in med-tech and a proven track record of turning ideas into global successes.

Why Laitek Fits Like a Glove

• Laitek’s expertise in data migration aligns perfectly with Enlitic’s vision of creating smarter, faster, and more integrated healthcare systems.
• By combining forces, the two companies can unlock untapped revenue streams and streamline healthcare tech on a massive scale.

This acquisition is more than a business deal—it’s a leap toward transforming the way healthcare systems handle data.

With Enlitic’s innovative AI solutions and Laitek’s expertise in medical imaging, this partnership promises better patient care, improved operational efficiency, and a lot of happy stakeholders.

Sources of information*

Announcements from https://www.asx.com.au/markets/company/enl

Company website https://enlitic.com/

DISCLAIMER: The information in this article does not constitute personal financial advice. Consult your adviser or stockbroker prior to making any investment decision.

MORE DISCLAIMERS: Stevo is not a Financial Adviser, however, works as an Investment Banker assisting ASX listed companies with retail capital raises. All opinions expressed and written by Stevo, including all other ‘Armchair Banker’ contributors is for informational and entertainment purposes only and should not be treated as investment or financial advice of any kind. Any information provided from our articles, blogs and written opinions is general in nature and does not take into account your specific circumstances. Armchair Banker and its contributors are not liable to the reader or any other party, for the reader’s use of, or reliance on, any information received, directly or indirectly, from any content by Armchair Banker in any circumstances.

The reader should always (we’re serious about this):

1. Conduct their own research

2. Never invest more than they are willing to lose

3. Obtain independent legal, financial, taxation and/or other professional advice in respect of any decision made in connection with this video.

Full Disclosure: Stevo has assisted this company with shareholder communications.

 For more articles, opinions information on this company and other ASX listed companies, SUBSCRIBE to the Armchair Banker newsletter!